$7.10
6.70%
Nasdaq, Thu, Sep 17 2026.
ISIN
US31572Q8087
Symbol
FGEN

FibroGen, Inc. Stock price

$7.10
+0.29 4.26% 1M
-0.27 3.66% 6M
-1.68 19.13% YTD
-4.04 36.27% 1Y
-12.65 64.05% 3Y
-285.15 97.57% 5Y
-525.40 98.67% 10Y
-542.90 98.71% 20Y
Nasdaq, Closing price Thu, Sep 17 2026
-0.51 6.70%
ISIN
US31572Q8087
Symbol
FGEN
Industry

Is FibroGen, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
positive
Cash
$118.0m
Shares outstanding
4.1m
Valuation (TTM | estimate)
P/E
0.1
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
-105.2%
Return on Equity
21.1%
ROCE
-121.3%
ROIC
-1,385.1%
Debt/Equity
-1.1
Financials (TTM | estimate)
Revenue
$8.3m | $6.9m
EBITDA
$-121.5m
EBIT
$-122.6m
Net Income
$215.7m
Free Cash Flow
$-17.1m
Growth (TTM | estimate)
Revenue
-95.4% | -76.8%
EBITDA
-34.7%
EBIT
-29.8%
Net Income
277.1%
Free Cash Flow
86.5%
Margin
Gross
345.7%
EBITDA
-1,464.1%
EBIT
-1,477.2%
Net
2,598.9%
Free Cash Flow
-206.0%
More
EPS
$53.3
FCF per Share
$-4.2
Short interest
3.3%
Employees
225
Rev per Employee
$130.0k

FibroGen, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a FibroGen, Inc. forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a FibroGen, Inc. forecast:

Buy
75%
Hold
25%

Financial data from FibroGen, Inc.

Sep '25
+/-
%
8.30 8.30
95% 95%
100%
- Direct Costs -20 -20
149% 149%
-246%
29 29
79% 79%
346%
- Selling and Administrative Expenses 7.14 7.14
92% 92%
86%
- Research and Development Expense 18 18
88% 88%
214%
-121 -121
35% 35%
-1,464%
- Depreciation and Amortization 1.09 1.09
74% 74%
13%
EBIT (Operating Income) EBIT -123 -123
30% 30%
-1,477%
Net Profit 216 216
277% 277%
2,598%

In millions USD.

Don't miss a Thing! We will send you all news about FibroGen, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.

Head office United States
CEO Mr. Wettig
Employees 225
Founded 1993
Website www.fibrogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today